liposomal bupivacaine local infiltration — Competitive Intelligence Brief

liposomal bupivacaine local infiltration (liposomal bupivacaine local infiltration) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesia/Pain Management.

marketed Local anesthetic Voltage-gated sodium channels Anesthesia/Pain Management Small molecule

Target snapshot

liposomal bupivacaine local infiltration (liposomal bupivacaine local infiltration) — Second Affiliated Hospital, School of Medicine, Zhejiang University. Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses when infiltrated into tissue.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
liposomal bupivacaine local infiltration TARGET	liposomal bupivacaine local infiltration	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Local anesthetic	Voltage-gated sodium channels
Bupivacaine Digital Block	Bupivacaine Digital Block	University of California, San Francisco	marketed	Local anesthetic	Voltage-gated sodium channels
Remifentanil, propofol and citanest	Remifentanil, propofol and citanest	University of Aarhus	marketed	General anesthetic combination	Mu opioid receptor (remifentanil); GABA-A receptor (propofol); Voltage-gated sodium channels (prilocaine)
bupivacaine(intraperitoneally)	bupivacaine(intraperitoneally)	Ain Shams University	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
Bupivacaine Hcl 0.5% Inj	Bupivacaine Hcl 0.5% Inj	Hospital for Special Surgery Florida	marketed	Local anesthetic	Voltage-gated sodium channels
Bupivacaine Injection [Marcaine]	Bupivacaine Injection [Marcaine]	South Egypt Cancer Institute	marketed	Local anesthetic	Voltage-gated sodium channels
Topiramate Standard	Topiramate Standard	Janssen Korea, Ltd., Korea	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class